Oxidopamine hydrochloride (6-Hydroxydopamine hydrochloride) |
| Catalog No.GC30871 |
Oxidopamine (6-OHDA) hydrochloride is an antagonist of the neurotransmitter dopamine.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 28094-15-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Oxidopamine hydrochloride (6-Hydroxydopamine hydrochloride) (6-OHDA) is an antagonist of the neurotransmitter dopamine[1]. Oxidopamine hydrochloride is a widely used neurotoxin that selectively destroys dopaminergic neurons[2]. Oxidopamine hydrochloride is often used to induce animal models of Parkinson's disease (PD)[3].
In vitro, 24h treatment of PC12 cells with Oxidopamine hydrochloride (0-150µM) induced chromatin condensation in a concentration- and time-dependent manner, increased the activity of caspase-3, -8, and -9 in cells, and depolarized the mitochondrial membrane[4]. 24h treatment of Neuro-2a and SH-SY5Y cells with Oxidopamine hydrochloride (0-500µM) reduced the viability of both cells in a concentration-dependent manner, with similar EC50 values(approximately 110µM), and induced cyclooxygenase-2 (COX-2) expression and nuclear translocation[5].
In vivo, Oxidopamine hydrochloride (8μg in 2μL saline) was injected into the medial forebrain bundle in old and young rats, which showed significant impairment in the contralateral forelimb reaching test and forced choice task, and a significant decrease in TH-expressing cells in the substantia nigra pars compacta (SNpc) and striatum[6]. Oxidopamine hydrochloride (5μg in 2μL saline) was injected unilaterally into the right striatum in SD rats, which induced nigrostriatal nerve terminal lesions, reduced striatal dopamine levels, and reduced the number of tyrosine hydroxylase immunoreactive cells in the ipsilateral substantia nigra, accompanied by significant atrophy of the remaining dopaminergic neurons[7].
References:
[1] De Boer P, Damsma G, Schram Q, et al. The effect of intrastriatal application of directly and indirectly acting dopamine agonists and antagonists on the in vivo release of acetylcholine measured by brain microdialysis: the importance of the post-surgery interval[J]. Naunyn-Schmiedeberg's archives of pharmacology, 1992, 345: 144-152.
[2] Pantic I, Cumic J, Skodric S R, et al. Oxidopamine and oxidative stress: Recent advances in experimental physiology and pharmacology[J]. Chemico-biological interactions, 2021, 336: 109380.
[3] Torres E M, Dunnett S B. 6-OHDA lesion models of Parkinson’s disease in the rat[J]. Animal Models of Movement Disorders: Volume I, 2012: 267-279.
[4] Fujita H, Ogino T, Kobuchi H, et al. Cell-permeable cAMP analog suppresses 6-hydroxydopamine-induced apoptosis in PC12 cells through the activation of the Akt pathway[J]. Brain research, 2006, 1113(1): 10-23.
[5] Kang X, Qiu J, Li Q, et al. Cyclooxygenase-2 contributes to oxidopamine-mediated neuronal inflammation and injury via the prostaglandin E2 receptor EP2 subtype[J]. Scientific reports, 2017, 7(1): 9459.
[6] Barata-Antunes S, Teixeira F G, Mendes-Pinheiro B, et al. Impact of aging on the 6-OHDA-induced rat model of Parkinson’s disease[J]. International journal of molecular sciences, 2020, 21(10): 3459.
[7] Jin F, Wu Q, Lu Y F, et al. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats[J]. European journal of pharmacology, 2008, 600(1-3): 78-82.
Average Rating: 5 (Based on Reviews and 10 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *